New Products

Premium

LabCorp has launched HCV GenoSure NS3/4A, a Sanger sequencing-based assay that reports mutations to NS3 and NS4A that are associated with resistance to boceprevir, telaprevir, and HCV protease inhibitors.

The assay was developed at Monogram Biosciences, and will be the first in a series of HCV drug resistance assays, according to the company. The test is available for clinical and commercial use.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.